Novel Herpes zoster vaccine (RZV)

Novel Herpes Zoster Vaccine 2 Dose

Price 14,800 THB

Shingrix®, a recombinant subunit zoster vaccine (RZV), is a novel, non-live vaccine that prevents herpes zoster (shingles) based on a specific protein of the varicella-zoster virus called glycoprotein E.

Shingrix® is highly effective, demonstrating 97% efficacy against herpes zoster in older adults aged 50 years and above. It is also effective against postherpetic neuralgia (PHN), a painful complication of shingles, with an efficacy of 91.2%. Ten years after Shingrix vaccination, the efficacy for the prevention of herpes zoster is still high, at 89%.

Shingrix® is a safe and effective vaccine that can help protect older adults from herpes zoster and its complications.

Individuals suitable for Shingrix® vaccination

• Individuals aged 50 and above. Shingrix® is administered intramuscularly, with the second dose given 2-6 months after the first dose.
• For individuals aged over 18 who are at higher risk of herpes zoster than other people, including immunocompromised individuals and those taking steroids, undergoing radiotherapy, and chemotherapy, two doses are administered 1-2 months apart.
• Individuals who have received zoster vaccine live (ZVL), give Shingrix® at least 2 months after receiving ZVL.
• Individuals who have had a previous episode of herpes zoster, give Shingrix® at least 6 months after.